Vatelizumab

DRUG2 trials

Sponsors

Genzyme, a Sanofi Company

Conditions

Relapsing-remitting Multiple Sclerosis

Phase 2

Efficacy and Safety of Vatelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

TerminatedNCT02222948

Genzyme, a Sanofi CompanyRelapsing-remitting Multiple Sclerosis

Start: 2014-09-30End: 2016-07-31Updated: 2016-12-21

Efficacy and Safety of Vatelizumab in Patients Who Completed Treatment in Study DRI13839

TerminatedNCT02306811

Genzyme, a Sanofi CompanyRelapsing-remitting Multiple Sclerosis

Start: 2015-02-28End: 2016-07-31Updated: 2016-12-21